[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578527":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":41,"responsibleParty":60,"collaborators":18,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":18,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"AHEPA University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Patients with RAO that will receive Rivaroxaban",[13],"Drug: Rivaroxaban",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Patients with RAO that will not receive any anticoagulation",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Rivaroxaban","Patients with RAO that will receive p.o. tabs Rivaroxaban 20 mg q.d.",[9],[26],{"name":27,"affiliation":28,"role":29},"Antonios Ziakas, Professor","AHEPA University Hospital, Thessaloniki, Greece","STUDY_CHAIR",[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Matthaios Didagelos, MD, MSc, PhD","CONTACT","2310994830","+30","manthosdid@yahoo.gr",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Areti Pagiantza, MD","2313303736","apayantza@gmail.com",[42],{"facility":5,"status":43,"city":44,"state":18,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Thessaloniki","54636","Greece","GR",{"type":49,"coordinates":50},"Point",[51,52],22.93493,40.64072,{"lat":52,"lon":51},[55,56,58,59],{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},{"name":38,"role":57,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"name":32,"role":57,"phone":18,"phoneExt":18,"email":18},{"name":27,"role":57,"phone":18,"phoneExt":18,"email":18},{"type":57,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Matthaios Didagelos","Consultant Interventional Cardiologist","100578527","phase-4-effect-of-rivaroxaban-in-radial-artery-occlusion-treatment-after-cardiac-catheterization-100578527",false,"NCT06812455","Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization","Effect of RIVAroxaban in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization","RIVA-RAO","Inclusion Criteria:\n\n1. Patients (both male and female) undergoing a coronary catheterization procedure (both angiography and PCI) through the transradial access and having successfully received at least one radial artery sheath of any size at the end of the procedure\n2. Radial artery occlusion confirmed by ultrasound (2D, Doppler, colour)\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Unable to provide informed written consent\n3. Any contraindication to receive Rivaroxaban","ALL","18 Years",{"count":74,"type":75},80,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The purpose of the RIVA-RAO study is to determine whether the use of Rivaroxaban is an effective treatment of radial artery occlusion (RAO) after cardiac catheterization (both angiography and PCI). This is a prospective, single-center, randomized controlled, open-label study that will randomize patients with RAO into two groups, one receiving Rivaroxaban and the other receiving no anticoagulation. RAO will be detected by radial artery ultrasound up to 24 hours after the procedure.\n\nStudy objectives:\n\nPrimary objective:\n\nTo evaluate the effect of treatment with Rivaroxaban, in patients (both symptomatic and asymptomatic) with RAO after a coronary catheterization procedure (both angiography and percutaneous coronary intervention-PCI), in improving patency rates of the radial artery at 4 weeks after the procedure, compared with no-anticoagulation treatment.\n\nSecondary objectives:\n\nTo compare local access site and systemic complications (bleeding events, pseudoaneurysm, arteriovenous fistula) at 4 weeks after the procedure between the two groups.",[81],"Radial Artery Occlusion",[83,84,85,86,87],"radial artery occlusion","complications","transradial","coronary catheterization","treatment","2025-02-09",{"date":90,"type":91},"2025-02-11","ACTUAL",{"date":93,"type":75},"2025-03-01",{"date":95,"type":75},"2029-03-01",{"name":5,"class":6},1]